TriSalus Life Sciences (TLSI) Projected to Post Earnings on Tuesday

Key Points

• TriSalus Life Sciences is set to announce its Q2 2025 earnings on August 12th, with analysts expecting earnings of ($0.22) per share and $10.69 million in revenue.
• In the previous quarter, TriSalus reported earnings of ($0.33) per share, missing estimates, while revenue exceeded expectations at $9.17 million.
• Goldman Sachs recently acquired new shares in TriSalus, buying 33,900 shares, which represents approximately 0.11% ownership of the company.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $10.69 million for the quarter.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The firm had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same quarter last year, the business posted ($0.60) EPS. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Trading Up 7.6%

Shares of TriSalus Life Sciences stock traded up $0.28 on Friday, reaching $3.95. 103,135 shares of the stock were exchanged, compared to its average volume of 57,636. TriSalus Life Sciences has a 1-year low of $3.46 and a 1-year high of $6.04. The business has a fifty day moving average price of $4.92 and a two-hundred day moving average price of $5.25. The firm has a market capitalization of $149.47 million, a PE ratio of -3.53 and a beta of 0.48.

Insider Buying and Selling

In related news, insider Richard Marshak sold 6,597 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the sale, the insider owned 69,101 shares of the company's stock, valued at approximately $357,943.18. The trade was a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 16,125 shares of company stock worth $83,528 over the last quarter. 27.50% of the stock is currently owned by insiders.

Institutional Trading of TriSalus Life Sciences

A hedge fund recently bought a new stake in TriSalus Life Sciences stock. Goldman Sachs Group Inc. acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 33,900 shares of the company's stock, valued at approximately $187,000. Goldman Sachs Group Inc. owned approximately 0.11% of TriSalus Life Sciences at the end of the most recent quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.